"
Team:Arizona State/Adjuvants
From 2013.igem.org
| (2 intermediate revisions not shown) | |||
| Line 12: | Line 12: | ||
</script> | </script> | ||
<body> | <body> | ||
| - | |||
| - | |||
<p> | <p> | ||
| - | + | Adjuvants are an important component of vaccine design that triggers a stronger immune response in patients. The adjuvants designed for the BactoVax system are detailed below: | |
</p> | </p> | ||
| + | |||
<h3>CpG Motifs</h3> | <h3>CpG Motifs</h3> | ||
<p> | <p> | ||
Synthetic CpG Oligodeoxynucleotides are short single-stranded synthetic DNA molecules that contain a cytosine triphosphate deoxynucleotide ("C)" followed by a guanine triphosphate deoxynucleotide ("G"). Because they are unmethylated, they act as immunostimulants. Because bacterial chassis contain a large number of unmethylated CG motifs in their genome, they provide a strong natural immunostimulant in parallel with antigen delivery. | Synthetic CpG Oligodeoxynucleotides are short single-stranded synthetic DNA molecules that contain a cytosine triphosphate deoxynucleotide ("C)" followed by a guanine triphosphate deoxynucleotide ("G"). Because they are unmethylated, they act as immunostimulants. Because bacterial chassis contain a large number of unmethylated CG motifs in their genome, they provide a strong natural immunostimulant in parallel with antigen delivery. | ||
</p> | </p> | ||
| + | <h3>GM-CSF</h3> | ||
| + | <p> | ||
| + | Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It is a cytokine that acts as a white blood cell growth factor and stimulates growth of granulocytes. It also induces monocytes to activate into macrophages, making it a potent activator of the immune response. GM-CSF causes rapid multiplication of macrophage numbers near infection sites and has been used to stimulate white blood cell development post-chemotherapy. The ASU iGEM team is engineering GM-CSF to be expressed and secreted from the bacterial vaccine chassis to: | ||
| + | <ol> | ||
| + | <li>Recruit Immune Cells, including Dendritic Cells, to engulf the vaccine and present the antigens via the MHC Class I pathway. This creates an antigen-presenting cell-targeted vaccine system.</li> | ||
| + | <li>Stimulate production of more immune cells to mount a stronger anti-tumor response.</li> | ||
| + | <li>Act as a potential factor for translational applications of the vaccine system in conjunction with chemotherapy to replenish white blood cell levels.</li> | ||
| + | </ol> | ||
| + | </p> | ||
| + | |||
</body> | </body> | ||
</html> | </html> | ||
Latest revision as of 02:20, 28 September 2013
Adjuvants are an important component of vaccine design that triggers a stronger immune response in patients. The adjuvants designed for the BactoVax system are detailed below:
CpG Motifs
Synthetic CpG Oligodeoxynucleotides are short single-stranded synthetic DNA molecules that contain a cytosine triphosphate deoxynucleotide ("C)" followed by a guanine triphosphate deoxynucleotide ("G"). Because they are unmethylated, they act as immunostimulants. Because bacterial chassis contain a large number of unmethylated CG motifs in their genome, they provide a strong natural immunostimulant in parallel with antigen delivery.
GM-CSF
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It is a cytokine that acts as a white blood cell growth factor and stimulates growth of granulocytes. It also induces monocytes to activate into macrophages, making it a potent activator of the immune response. GM-CSF causes rapid multiplication of macrophage numbers near infection sites and has been used to stimulate white blood cell development post-chemotherapy. The ASU iGEM team is engineering GM-CSF to be expressed and secreted from the bacterial vaccine chassis to:
- Recruit Immune Cells, including Dendritic Cells, to engulf the vaccine and present the antigens via the MHC Class I pathway. This creates an antigen-presenting cell-targeted vaccine system.
- Stimulate production of more immune cells to mount a stronger anti-tumor response.
- Act as a potential factor for translational applications of the vaccine system in conjunction with chemotherapy to replenish white blood cell levels.
